所有图片(1)
About This Item
经验公式（希尔记法）:
C22H38O5
CAS号:
分子量:
382.53
MDL编号:
UNSPSC代码:
41116107
PubChem化学物质编号:
NACRES:
NA.24
等级
pharmaceutical primary standard
API类
misoprostol
制造商/商品名称
EDQM
应用
pharmaceutical (small molecule)
格式
neat
储存温度
−20°C
SMILES字符串
CCCCC(C)(O)C\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)OC
InChI
1S/C22H38O5/c1-4-5-14-22(2,26)15-10-12-18-17(19(23)16-20(18)24)11-8-6-7-9-13-21(25)27-3/h10,12,17-18,20,24,26H,4-9,11,13-16H2,1-3H3/b12-10+/t17-,18-,20-,22?/m1/s1
InChI key
OJLOPKGSLYJEMD-URPKTTJQSA-N
基因信息
human ... PTGER3(5733)
正在寻找类似产品? 访问 产品对比指南
一般描述
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.
应用
Misoprostol EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
生化/生理作用
PGE 1 类似物前体药物，迅速去酯化为活性“米索前列醇酸”。广泛的治疗作用，包括预防 NSAID 诱导的胃溃疡、调节免疫级联反应、抑制血小板活化因子（PAF）、治疗乙醇和扑热息痛诱导的肝毒性和肝炎以及刺激损伤后的软骨修复。
包装
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
其他说明
Sales restrictions may apply.
警示用语：
Danger
危险声明
危险分类
Acute Tox. 3 Oral - Repr. 1B
WGK
WGK 3
闪点(°F)
Not applicable
闪点(°C)
Not applicable
Christina S Chu et al.
Journal of the Royal Society of Medicine, 105(8), 336-347 (2012-08-22)
This article describes and critically appraises clinical trials assessing misoprostol effectiveness in preventing primary postpartum haemorrhage (PPH) in home and community settings in low- and middle-income countries. Of 172 identified studies of misoprostol use in labour only six fulfilled the
V A Hundley et al.
BJOG : an international journal of obstetrics and gynaecology, 120(3), 277-285 (2012-11-30)
Using misoprostol to prevent postpartum haemorrhage (PPH) in home-birth settings remains controversial. To review the safety and effectiveness of oral misoprostol in preventing PPH in home-birth settings. The Cochrane Library, PubMed, and POPLINE were searched for articles published until 31
Jeffrey Michael Smith et al.
BMC pregnancy and childbirth, 13, 44-44 (2013-02-21)
Hemorrhage continues to be a leading cause of maternal death in developing countries. The 2012 World Health Organization guidelines for the prevention and management of postpartum hemorrhage (PPH) recommend oral administration of misoprostol by community health workers (CHWs). However, there
C W Ho et al.
Alimentary pharmacology & therapeutics, 37(8), 819-824 (2013-02-26)
Poor adherence to gastroprotective agents (GPAs) is common among users of nonsteroidal anti-inflammatory drugs (NSAIDs) or low-dose aspirin (ASA). There are little data on the utilization of GPAs among NSAID and ASA users complicated by ulcer bleeding. To study the
Heleen J van Beekhuizen et al.
International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics, 122(3), 234-237 (2013-06-25)
To evaluate the efficacy and safety of misoprostol among patients with retained placenta in a low-resource setting. A prospective, multicenter, randomized, double-blind, placebo-controlled trial was carried out in Tanzania between April 2008 and November 2011. It included patients who delivered
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门